Literature DB >> 18707887

Cerebellar diaschisis and contralateral thalamus hyperperfusion in a stroke patient with complex regional pain syndrome.

Min-Hsin Lai1, Tzu-Yun Wang, Cheng-Chiang Chang, Tsung-Ying Li, Shin-Tsu Chang.   

Abstract

We present a right-hemispheric stroke patient with complex regional pain syndrome (CRPS). The regional cerebral blow flow (rCBF) as determined using single photon emission computed tomography (SPECT) showed contralateral increase of tracer uptake in the left thalamus accompanied by crossed cerebellar diaschisis (CCD) in the left cerebellum. After rehabilitation, the CRPS in the right upper extremity recovered, although hemiplegia persisted on the left limbs. The rCBF determined a second time using SPECT showed that uptake was normal in the bilateral thalami, basal ganglia and bilateral cerebella. At a 6-month follow-up, the CRPS had not recurred. Our findings show that analysis of rCBF by SPECT is useful for the clinical evaluation and follow-up of CRPS. To the best of our knowledge, this is the first reported case with this particular pattern of symptoms amd symptom resolution.

Entities:  

Mesh:

Year:  2008        PMID: 18707887     DOI: 10.1016/j.jocn.2007.06.017

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

Review 1.  Central nervous system involvement in diabetic neuropathy.

Authors:  Dinesh Selvarajah; Iain D Wilkinson; Jennifer Davies; Rajiv Gandhi; Solomon Tesfaye
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

2.  Correlation of thalamic blood flow redistribution with persistent complex regional pain syndrome in a stroke patient with poor diabetic control.

Authors:  Kao-Chih Hsu; Shin-Tsu Chang
Journal:  J Diabetes Investig       Date:  2013-07-12       Impact factor: 4.232

3.  Crossed Cerebellar Diaschisis: Three Case Reports Imaging Using a Tri-Modality PET/CT-MR System.

Authors:  Shuguang Han; Xiaopeng Wang; Kai Xu; Chunfeng Hu
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.